Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jiefei Han

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Cancer Immunology Research|November 14, 2019
TCR Repertoire Diversity of Peripheral PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non-Small Cell Lung CancerJiefei Han, Jianchun Duan, Hua Bai, et al.
Journal for Immunotherapy of Cancer|July 28, 2019
Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancerLiangliang Cai, Hua Bai, Jianchun Duan, et al.
Nature Communications|February 8, 2024
Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapyJiefei Han, Yiting Dong, Xiuli Zhu, et al.
Science Advances|June 17, 2021
Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non-small cell lung cancersJiefei Han, Ruofei Yu, Jianchun Duan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2018
Prediction of Chemotherapeutic Efficacy in Non-Small Cell Lung Cancer by Serum Metabolomic ProfilingYanhua Tian, Zhijie Wang, Xiaohui Liu, et al.
Ebiomedicine|July 28, 2022
Genomic and epigenomic profiles distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancerYing Zuo, Jia Zhong, Hua Bai, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib TreatmentJianchun Duan, JiaChen Xu, Zhijie Wang, et al.
JAMA Oncology|March 1, 2019
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene PanelZhijie Wang, Jianchun Duan, Shangli Cai, et al.
The Journal of Thoracic and Cardiovascular Surgery|February 11, 2024
Treatment patterns and clinical outcomes of patients with resectable non-small cell lung cancer receiving neoadjuvant immunochemotherapy: A large-scale, multicenter, real-world study (NeoR-World)Zhenlin Yang, Shuaibo Wang, Haitang Yang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2019
Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 InhibitorsZhijie Wang, Jianchun Duan, Guoqiang Wang, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Cancer Immunology Research|November 14, 2019
TCR Repertoire Diversity of Peripheral PD-1<sup>+</sup>CD8<sup>+</sup> T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non-Small Cell Lung CancerJiefei Han, Jianchun Duan, Hua Bai, et al.
Journal for Immunotherapy of Cancer|July 28, 2019
Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancerLiangliang Cai, Hua Bai, Jianchun Duan, et al.
Nature Communications|February 8, 2024
Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapyJiefei Han, Yiting Dong, Xiuli Zhu, et al.
Science Advances|June 17, 2021
Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non-small cell lung cancersJiefei Han, Ruofei Yu, Jianchun Duan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2018
Prediction of Chemotherapeutic Efficacy in Non-Small Cell Lung Cancer by Serum Metabolomic ProfilingYanhua Tian, Zhijie Wang, Xiaohui Liu, et al.
Ebiomedicine|July 28, 2022
Genomic and epigenomic profiles distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancerYing Zuo, Jia Zhong, Hua Bai, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib TreatmentJianchun Duan, JiaChen Xu, Zhijie Wang, et al.
JAMA Oncology|March 1, 2019
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene PanelZhijie Wang, Jianchun Duan, Shangli Cai, et al.
The Journal of Thoracic and Cardiovascular Surgery|February 11, 2024
Treatment patterns and clinical outcomes of patients with resectable non-small cell lung cancer receiving neoadjuvant immunochemotherapy: A large-scale, multicenter, real-world study (NeoR-World)Zhenlin Yang, Shuaibo Wang, Haitang Yang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2019
Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 InhibitorsZhijie Wang, Jianchun Duan, Guoqiang Wang, et al.
Pageof 2